ALX Oncology Holdings Inc. (ALXO) annual cash flow statement — 8-year operating, investing & financing history
ALX Oncology Holdings Inc. (ALXO) cash flow statement — 8-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Cash from Operations | -89.43M | -84.14M | -121.91M | -130.36M | -89.22M | -68.1M | -38.29M | -14.25M | -13.19M |
| Operating CF Margin % | - | - | - | - | - | - | -3239.34% | -297.1% | -638.12% |
| Operating CF Growth % | 49.53% | 30.98% | 6.48% | -46.11% | -31.02% | -77.86% | -168.71% | -8.03% | - |
| Net Income | -80.89M | -101.69M | -134.85M | -160.81M | -123.48M | -83.46M | -45.74M | -19.24M | -13.73M |
| Depreciation & Amortization | 690K | 706K | 872K | 836K | 342K | 51K | 202K | 429K | 431K |
| Stock-Based Compensation | 12.93M | 12.58M | 27.09M | 26.27M | 23.84M | 13.91M | 5.44M | 297K | 269K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -329K | 3.93M | -2.6M | -4.96M | 228K | 5.42M | 1.57M | 11K | 2.33M |
| Working Capital Changes | -3.9M | 336K | -12.43M | 8.3M | 9.85M | -4.03M | 247K | 4.26M | -159K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 536K | 396K | -932K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -3.17M | 421K | -4.02M | 458K | 4.51M | 3.29M | -3.74M | 2.98M | -269K |
| Cash from Investing | -170.92M | 82.59M | 86.26M | 44.66M | -235.42M | -4.92M | 610K | -353K | -653K |
| Capital Expenditures | -222K | -212K | -447K | -1.27M | -1.43M | -666K | -31K | -353K | -653K |
| CapEx % of Revenue | - | - | - | - | - | - | 2.62% | 7.36% | 31.59% |
| Acquisitions | 0 | 0 | 0 | 0 | 233.99K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 44K | 0 | 0 | 0 | -233.99K | -4.26M | 641K | 0 | 0 |
| Cash from Financing | 279.85M | 362K | 30.82M | 59.29M | 9.86M | 2.47M | 462.88M | 15.36M | 1K |
| Debt Issued (Net) | 4.42M | -1.36M | -827K | -388K | 9.61M | -281K | 0 | 5.92M | 0 |
| Equity Issued (Net) | 293.34M | 1.73M | 31.64M | 58.89M | 903K | 2.75M | 472.94M | 9.43M | -6K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6K |
| Other Financing | -17.91M | 0 | 0 | 792K | -655K | 0 | -10.05M | 10K | 7K |
| Net Change in Cash | 19.5M | -1.19M | -4.84M | -26.42M | -314.78M | -70.55M | 425.2M | 755K | -13.84M |
| Free Cash Flow | -89.65M | -84.35M | -122.36M | -131.64M | -90.65M | -73.02M | -38.32M | -14.6M | -13.84M |
| FCF Margin % | - | - | - | - | - | - | -3241.96% | -304.46% | -669.71% |
| FCF Growth % | 15.27% | 31.06% | 7.05% | -45.22% | -24.14% | -90.56% | -162.43% | -5.48% | - |
| FCF per Share | -0.66 | -1.57 | -2.35 | -3.06 | -2.23 | -1.81 | -0.96 | -0.67 | -0.63 |
| FCF Conversion (FCF/Net Income) | 1.11x | 0.83x | 0.90x | 0.81x | 0.72x | 0.82x | 0.84x | 0.74x | 0.96x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 11K | 427K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 274K | 47K | 0 | 0 |
Quick answers to the most common questions about buying ALXO stock.
ALX Oncology Holdings Inc. (ALXO) generated $-84.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
ALX Oncology Holdings Inc. (ALXO) reported negative free cash flow of $84.4M in 2025, indicating capital requirements exceeded cash from operations.
ALX Oncology Holdings Inc. (ALXO) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.